Towards Predicting Individual Cognitive Trajectories in Alzheimer’s Disease using Quantitative Systems Pharmacology Poster 运用定量系统药理学预测阿尔茨海默病患者的个体认知轨迹 About Functional readouts in Alzheimer's Disease is highly variable due to different comedications, genotypes, amyloid-…Renee Fisher2024 年 11 月 22 日
Effects of Anti-Amyloid Treatment on Tau Biomarkers and Functional Outcome Poster 抗淀粉样蛋白治疗对 Tau 生物标志物和功能结果的影响 About There are major unaddressed issues in Alzheimer's Disease clinical practice such as: Identifying accessible…Renee Fisher2024 年 11 月 22 日
A Mechanistic PK/PD Model for First-in-Human Dosing of a Tetraspecific Antibody (MDX2001) for the Treatment of Advanced Solid Tumors Poster 用于治疗晚期实体瘤的四特异性抗体(MDX2001)首次人体试验给药的机制 PK/PD 模型 MDX2001 is a tetraspecific T cell engager that binds CD3 and CD28 on T cells…Renee Fisher2024 年 11 月 22 日
Quantitative Systems Pharmacology Model for Therapies Targeting Aβ and tau Pathologies in Alzheimer’s Disease Poster 针对阿尔茨海默病中 Aβ 和 tau 病理的治疗方法的定量系统药理学模型 Renee Fisher2024 年 11 月 14 日
Model-Informed Drug Development (MIDD) to Accelerate ADC Development and Maximize Therapeutic Index Poster 模型引导的药物开发 (MIDD),加快 ADC 开发并最大限度地提高治疗指数 Renee Fisher2024 年 11 月 14 日
ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation Publication ATG-101 是一种四价 PD-L1×4-1BB 双特异性抗体,通过阻断 PD-L1 及 PD-L1 导向的 4-1BB 激活来刺激抗肿瘤免疫 Abstract Immune checkpoint inhibitors (ICI) have transformed cancer treatment. However, only a minority of patients…Renee Fisher2024 年 11 月 13 日
Clinical Candidate Selection Case Study 临床候选者遴选 In this case study, we look at an example of targeting a membrane bound protein…Renee Fisher2024 年 10 月 31 日
Phase 1 Interim Analysis Case Study 第 I 阶段中期分析 In this case study, we continue to work with the model and analysis from Immuno-modulation…Renee Fisher2024 年 10 月 31 日
Improved Translation of Clinical TCE Dosing with Mechanistic Modeling On-Demand Webinar 利用机制建模优化临床 TCE 给药方案的转化 摘要:Regulatory agencies recommend quantitative justifications for clinical dose selection. T-cell engagers (TCE) pose particular…Renee Fisher2024 年 10 月 31 日
Applications of a QSP Model of LNP mRNA Delivery for the Treatment of Crigler-Najjar Syndrome Type 1 On-Demand Webinar 应用 QSP 模型传递 LNP mRNA 治疗 1 型克里格勒-纳贾尔综合征(Crigler-Najjar Syndrome) 摘要:Crigler-Najjar syndrome type 1 (CN1) is an autosomal recessive disease caused by a marked…Renee Fisher2024 年 10 月 31 日